Therapeutic horizons of indirect oral anticoagulants

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article is devoted to summarizing the data on the use of indirect oral anticoagulants (IOACs). A broad therapeutic platform for preventing thrombotic complications using drugs of this group is shown. The prospects for the use of IOACs in patients with new coronavirus infection are indicated. A promising domestic drug of this group has been named, which, among well-known competitors such as rivaroxaban, apixaban, edoxaban and betrixaban, shows one of the lowest concentrations required to double prothrombin time, which researchers associate with tight binding between the ligand-drug and the amino acids Gly216 and Gly218 target protein.

Full Text

Restricted Access

About the authors

Sergey V. Zakharov

Korolev City Hospital

Author for correspondence.
Email: zakharov-sv@inbox.ru
ORCID iD: 0009-0002-1565-6304

Neurologist

Russian Federation, Moscow region Korolev

A. Yu. Savchenko

Scientific Center for Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Email: zakharov-sv@inbox.ru
ORCID iD: 0000-0003-2734-5036
Russian Federation, Moscow region, Svetlye Gory

References

  1. Weinberg E.M., Palecki J., Reddy K.R. Direct-acting Oral Anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis. 2019;39(2):195–208. doi: 10.1055/s-0039-1679934.
  2. Сомонова О.В., Елизарова А.Л. Возможности апиксабана в лечении и профилактике рецидивов онкоассоциированных тромбозов. Лечебное дело. 2023;(1):45–51. [Somono-va O.V., Elizarova A.L. Abilities of apixaban in treatment and prevention of recurrent cancer-associated thrombosis. Lech Delo. 2023;(1):45–51. (In Russ.)]. doi: 10.24412/2071-5315-2023-12947.
  3. Середавкина Н.В., Решетняк Е.М., Сатыбалдые-ва М.А. и др. Эффективность и переносимость селективных и неселективных ингибиторов Ха-фактора при антифосфолипидном синдроме и системной красной волчанке: уровень анти-Ха-активности. Терапевтический архив. 2019;(5):19–25. [Seredavkina N.V., Reshetny-ak T.M., Satybaldyeva M.A., et al. Effectiveness and safety of selective and non-selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti-Xa-activity range. Ter Arkh. 2019;(5):19–25. (In Russ.)]. doi: 10.26442/00403660.2019.05.000235.
  4. Gibson P.S. Anticoagulants and pregnancy: when are they safe? Сlevel Clin J Med. 2009;76(2):113–27. doi: 10.3949/ccjm.75a.072272.
  5. Buller H.R., Prins M.H., Lensin A.W. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97. doi: 10.1056/nejmoa1113572.
  6. Bauersachs R., Berkowitz S.D., Brenner B. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510. doi: 10.1056/nejmoa1007903.
  7. European medicines agency. Annex I summary of product characteristics. 2018. Available from: URL: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
  8. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. doi: 10.1056/nejmoa1009638.
  9. Jiang H., Jiang Y., Ma H., et al. Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta‐analysis. Clin Cardiol. 2021;44(9):1208–15. doi: 10.1002/clc.23690.
  10. Gibson W.J., Gibson C.M., Megan K., et al. Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post‐acute coronary syndrome patients: A pooled analysis study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51. JAHA. 2019;8(5):e009451. doi: 10.1161/JAHA.118.009451.
  11. Anderson D.R., Dunbar M., Murnaghan J., et al. Aspirin or Rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378 (8):699–707. doi: 10.1056/nejmoa1712746.
  12. Martinez Licha C.R., McCurdy C.M., Maldonado S.M., Lee L.S. Current management of acute pulmonary embolism. Ann Thorac Cardiovasc Surg. 2020;26 (2):65–71. doi: 10.5761/atcs.ra.19-00158.
  13. Le G., Yang C., Zhang M., et al. Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty. A protocol for meta-analysis. Medicine (Baltimore). 2020;99 (49):e23055. doi: 10.1097/md.0000000000023055.
  14. Федина Л.В., Сычев Б.Н., Сычев Д.А. Актуальность использования фармакогенетического подхода для прогнозирования индивидуальных особенностей фармакокинетики и профиля безопасности апиксабана. Фармакогенетика и фармакогеномика. 2021;(1):4–8. [Fedina L.V., Sychev B.N., Sychev D.A. Importance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixaban. Farmakogenet. Farmakogenom. 2021;(1):4–8. (In Russ.)]. doi: 10.37489/2588-0527-2021-1-4-8.
  15. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17. doi: 10.1056/nejmoa1007432.
  16. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi: 10.1056/nejmoa1107039.
  17. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807–15. doi: 10.1016/s0140-6736(09)62125-5.
  18. Picard F., Van Ganse E., Ducrocq G., et al. Evaluation of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study. Clin Cardiol. 2019;42(10):851–59. doi: 10.1002/clc.23231.
  19. Панченко Е.П., Балахонова Т.В., Данилов Н.М. и др. Диагностика и лечение тромбоэмболии легочной артерии: клинические рекомендации для практических врачей Евразийской ассоциации кардиологов. Евразийский кардиологический журнал. 2021;(1):6–43. [Panchenko E.P., Balahonova T.V., Danilov N.M., et al. Diagnosis and management of pulmonary embolism eurasian association of cardiology (eac) clinical practice guidelines (2021). Evraz. Сardiol. J. 2021;(1):6–43. (In Russ.)]. doi: 10.38109/2225-1685-2021-1-44-77.
  20. Eikelboom J.W. Explaining the RE-LY trial. Can. J. Hosp. Pharm. 2010;63(4):334–6. doi: 10.4212/cjhp.v63i4.941.
  21. Bartlett J.W., Renner E., Mouland E., et al. Clinical safety outcomes in patients with nonvalvular atrial fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21–7. doi: 10.1177/1060028018795140.
  22. Божкова С.А., Касимова А.Р., Накопия В.Б., Корнилов Н.Н. Все ли мы знаем о профилактике венозных тромбоэмболических осложнений после больших ортопедических операций? Травматология и ортопедия России. 2018;24(1):129–43. [Bozhkova S.A., Kasimova A.R., Nakopia V.B., Kornilov N.N. Do we know all about prevention of venous thromboembolism after major orthopedic surgery? Travmatol. Ortoped. Ros. 2018;24(1):129–43. (In Russ.)]. doi: 10.21823/2311-2905-2018-24-1-129-143.
  23. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4–2):1–52. [Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebol. 2015;9(4–2):1–52. (In Russ.)].
  24. Переверзев А.П., Остроумова О.Д., Ткачева О.Н., Котовская Ю.В. Осложнения фармакотерапии новыми оральными антикоагулянтами, вызванные межлекарственным взаимодействием: акцент на желудочно-кишечные кровотечения. Безопасность и риск фармакотерапии. 2019;7(2):65–71. [Pereverzev A.P., Ostroumova O.D., Tkacheva O.N., Kotovskaya Yu.V. Complications of Pharmacotherapy with New Oral Anticoagulants Caused by Inter-Drug Interactions: Focus on Gastrointestinal Bleeding. Bezopasnost’ i risk farmakoterapii. 2019;7(2):65–71. (In Russ.)]. doi: 10.30895/2312-7821-2019-7-2-65-71.
  25. Кузнецова С.А., Васильева Н.Ю., Дроз Н.Н. и др. Сульфатированные производные арабиногалактана и их антикоагулянтная активность. Химия растительного сырья. 2019;(4):47–56. [Kuznetsova S.A., Vasil’eva N.Yu., Droz N.N., et al. Sulfated arabinogalactan derivatives and their anticoagulant activity. Khimiya rastitel’nogo syr’ya. 2019;(4):47–56. (In Russ.)]. doi: 10.14258/jcprm.2019044845.
  26. Титаева Е.В., Добровольский А.Б. Хромогенный антиХа-тест: соотношение между единицами активности гепарина и концентрацией апиксабана и ривароксабана. Атеротромбоз. Специальный медицинский журнал. 2020;(2):96–104. doi: 10.21518/2307-1109-2020-2-96-104. [Titaeva E.V., Dobrovol’skiy A.B. Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban. Aterotromboz. Spets Med J. 2020;(2):96–104. (In Russ.)].
  27. Talasaz A.H., Sadeghipour P., Kakavand H., et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77(15):1903–21. doi: 10.1016/j.jacc.2021.02.035.
  28. Bohula E.A., Giugliano R.P., Leiter L.A., et al. Inflammatory and cholesterol risk in the FourIier trial. Circulation. 2018;138(2):131–40. doi: 10.1161/circulationaha.118.034032.
  29. Bikdeli B., Madhavan M.V, Jimenez D., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950–73. doi: 10.1016/j.jacc. 2020.04.031.
  30. National Prescription Audit (NPA) and IMS. Total patient tracker (TPT) databases. October 2010-December 2013. Available from: URL: https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data.
  31. Nadkarni G.N. Lala A., Bagiella E., et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(16):1815–26. doi: 10.1016/j.jacc.2020.08.041.
  32. SIGN. Prevention and management of venous thromboembolism: a national clinical guideline. Edinburgh: SIGN, 2010.
  33. Santos B.C., Flumignan R.L., Civile V.T., et al. Prophylactic anticoagulants for non-hospitalised people with COVID-19 (Protocol). Cochrane Database Syst Rev. 2023;8(8):CD015102. doi: 10.1002/14651858.cd015102.pub2.
  34. Khadse A.N., Sharma M.K., Murumkar P.R., et al. Advances in the development of novel factor Xa inhibitors: A patent review. Mini Rev Med Chemistry. 2018;18(16):1332–53. doi: 10.2174/1389557518666180424120726.
  35. Tovbin D.G., Tarasov D.N., Malakhov D.V., et al. The development of new low-molecular-weight factor Xa inhibitors that are potential anticoagulants. Curr Drug Discov Technol. 2022;19(1):e010921191770. doi: 10.2174/1568009621666210224104940.
  36. Fredenburgh J.C., Weitz J.I. News at XI: moving beyond factor Xa inhibitors. J. Thromb. Haemostas. 2023;21(7):1692–702. doi: 10.1016/j.jtha.2023.04.021.
  37. Гильдеева Г.Н., Чапленко А.А., Юрков В.И., Степанова Е.С. Сравнительное изучение биоэквивалентности препаратов, содержащих ривароксабан, при однократном приеме здоровыми добровольцами. Безопасность и риск фармакотерапии. 2022;10(3):293–301. [Gildeeva G.N., Chaplenko A.A., Yurkov V.I., Stepanova E.S. Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy Volunteers. Bezopasnost’ i risk farmakoterapii. 2022;10(3):293–301. (In Russ.)]. doi: 10.30895/2312-7821-2022-10-3-293-301.
  38. Quan M.L., Pinto D.J.P., Smallheer J.M., et al. Factor XIa inhibitors as new anticoagulants. J Med Chem. 2018;61(17):7425–47. doi: 10.1021/acs.jmedchem.8b00173.
  39. Shulga D.A., Tserkovnikova N.A., Tarasov D.N., Tovbin D.G. Investigation of the tight binding mechanism of a new anticoagulant DD217 to factor Xa by means of molecular docking and molecular dynamics. J Biomol Struct Dyn. 2022;41:4723–34. doi: 10.1080/07391102.2022.2072387.
  40. Tarasov D.N., Tovbin D.G., Malakhov D.V., et al. The development of new factor Xa inhibitors based on amide synthesis. Curr Drug Discov Technol. 2018;15(4):335–50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies